Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FIAsp After Different Injection Regions and Routes
NCT02089451Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin aspart in diabetes mellitus (DM), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration). Started Mar 2014; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02089451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089451.